Purple Biotech in the first quarter: IM1240 advances, but cash is the near test

The first quarter reinforces that Purple Biotech is no longer a balanced story across several clinical assets, but a company increasingly centered on CAPTN-3 and IM1240 as the nearest value driver. The new patient-derived tumor-sample data gives the company another scientific support layer: all tested samples responded to IM1240 exposure, including treatment-resistant samples, and the NKG2A arm continues to look like a meaningful part of the product's differentiation. But this is still preclinical work, not evidence of efficacy in treated patients, so the practical question remains how much time and cash are needed before the science reaches the clinic. That is where the quarter is less comfortable: cash and short-term deposits declined from about $9.6 million at the end of 2025 to about $6.4 million at the end of March, operating cash flow was negative by $3.1 million, and the adjusted loss increased. The reported net loss of only $0.1 million looks better because the company recorded non-cash income from changes in warrant fair value. The current read is not that Purple failed during the quarter, but that 2026 has become a tighter proof year: the science gained encouraging support, while the financial runway to a first-in-human study is not wide.

Company Setup

Purple Biotech is a life-sciences company at a clinical-stage level, but its economics today do not resemble a company selling an approved product or building revenue. It is financing time until clinical milestones and trying to turn early data into value that can attract a partner, financing, or better equity terms. That is the core context for the first quarter: every scientific improvement should be tested by whether it extends the path or improves financing conditions, not by a conventional income-statement lens.

The center of activity has shifted to CAPTN-3, a platform of masked tri-specific antibodies designed to activate T cells and NK cells inside the tumor microenvironment. The lead candidate is IM1240, while IM1305, targeting TROP2, is also in preclinical development. CM24 and NT219 remain in the pipeline, but further development depends on partnering or additional investment. That matters: the older assets may still return value, but they are no longer where the company is allocating most of its resources.

The previous coverage focused on this exact gap. The 2025 annual analysis framed Purple as a company whose center of gravity had shifted to IM1240, and the IM1240 financing analysis asked whether the cash balance was enough to get the program into the clinic. The first quarter does not close that question. It adds scientific evidence, but also shortens the financial distance to the next decision point.

The New Data Supports IM1240, But It Does Not Make It Clinical Yet

The scientific update is stronger than the financial numbers. Patient-derived tumor samples generated with Amir Horowitz's lab at Mount Sinai all responded to IM1240 exposure. The company also reported activity in resistant samples, including PD-1 or PD-1 plus chemotherapy-resistant head and neck cancer metastatic lymph-node samples, and enfortumab vedotin plus PD-1-resistant muscle-invasive bladder cancer. In a non-small cell lung cancer biopsy, IM1240 induced mature tertiary lymphoid structures associated with anti-tumor immune response and favorable prognosis.

The more important point is the NKG2A contribution. The company emphasized that the NKG2A arm significantly enhanced anti-tumor activity across tested samples and improved the therapeutic index. For CAPTN-3, that is an important differentiation claim because the platform's promise is not only to attack tumors, but to do so without expanding immune-activation toxicity too broadly.

Still, the data belongs in the right place. These are patient-derived samples, not patients treated in a clinical trial. The update strengthens the rationale for continuing IM1240 development, but it does not replace an IND, a Phase 1 start, or human safety data. The CAPTN-3 Scientific Advisory Board and the expanded Converge Bio collaboration support the development process, but they are not new cash and not a partnership deal. They improve scientific execution quality, not the cash position.

The Reported Net Loss Improved, But Adjusted Loss And Cash Worsened

The eye-catching number is a net loss of only $89 thousand in the first quarter, compared with $456 thousand in the prior-year quarter. That is not a real decline in spending pace. Operating loss increased to $2.25 million, adjusted operating loss increased to $2.16 million, and adjusted net loss increased to $2.17 million. The gap exists because the company recorded $2.17 million of income from changes in warrant fair value, a non-cash accounting item.

The increase also shows up in operating expenses. Research and development expenses rose to $1.23 million, mainly because of chemistry, manufacturing, and controls activity related to CAPTN-3. General and administrative expenses rose to $1.02 million, mainly because of payroll, professional services, and related expenses. That fits a year in which the company wants to push a new platform toward first-in-human studies, but it also means that the lower expense base of 2025 is not necessarily a comfortable comparison point anymore.

On an all-in cash-flexibility basis, meaning cash left after the quarter's actual cash uses rather than a maintenance-spend estimate, the pressure is clearer. Cash and short-term deposits fell from about $9.57 million at the end of 2025 to about $6.43 million at the end of March. Operating cash flow was negative by $3.12 million, compared with a negative $1.98 million in the prior-year quarter. Part of the use came from a $1.24 million decline in accounts payable, so this quarter is not necessarily a clean burn-rate that repeats one-for-one. But even after that caveat, the cash cushion no longer looks spacious.

2026 Will Decide Whether This Is A Bridge To The Clinic Or Another Financing Before Proof

The company expects the current cash position to provide runway into 2027. That statement matters, but it does not say the cash reaches a meaningful clinical readout. IM1240 and IM1305 are still moving toward first-in-human studies in 2027, and during the rest of 2026 the company plans to generate additional efficacy evidence across potential indications and advance new tri-specific antibody combinations. This is a proof year, not a clinical-results year: the market is likely to measure whether IM1240 keeps moving toward an IND and human testing, and whether spending stabilizes before the cash balance gets too close to the next financing point.

The credible counter-thesis is that the first quarter actually strengthened the story: IM1240 received more data, the company built a scientific advisory board around CAPTN-3, the Converge Bio collaboration may improve the design of next-generation antibodies, and there is no financial debt requiring immediate refinancing. That is a reasonable argument, but it is not enough by itself. CM24 and NT219 still need a partner or dedicated investment to return as active assets, and negligible short interest shows that pressure is coming from capital structure rather than a major short base. As long as progress remains preclinical and cash fell by more than $3 million in the quarter, the next proof has to be two-sided: more data that brings IM1240 closer to the clinic, and a cash picture showing the company can get there without buying time through excessively dilutive financing.